HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ORCL
Oracle Corporation
ORCL's fundamentals are mixed, but it looks cheap: trading at 20x earnings, below its usual 30x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ORCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
ORCL's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ORCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $127 | — |
| Cheap | 19x | $119 | -6.8% |
| Current | 20x | $127 | — |
| Fair | 30x | $189 | +49% |
| Expensive | 39x | $247 | +94% |
Historical ranges are pointers, not guarantees.
ORCL's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ORCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for ORCL, but weaker profitability.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ORCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.53 | +34% |
| Q3 2026 | $6.38 | +48% |
| Q2 2026 | $5.83 | +34% |
| Q1 2026 | $5.57 | +31% |
| Q4 2025 | $5.32 | +30% |
| Q3 2025 | $4.32 | +11% |
| Q2 2025 | $4.34 | +17% |
| Q1 2025 | $4.26 | +12% |
| Q4 2024 | $4.09 | +13% |
ORCL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ORCL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ORCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3B | +30% |
| Q2 2026 | $19.2B | +21% |
| Q1 2026 | $17.2B | +22% |
| Q4 2025 | $16.1B | +14% |
| Q3 2025 | $14.9B | +12% |
| Q2 2025 | $15.9B | +11% |
| Q1 2025 | $14.1B | +6.4% |
| Q4 2024 | $14.1B | +8.6% |
ORCL's revenue has grown year over year for 13 quarters in a row: $19.3B last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | +6.1 points |
| Q2 2026 | 32% | -0.2 points |
| Q1 2026 | 32% | +0.9 points |
| Q4 2025 | 29% | -0.6 points |
| Q3 2025 | 29% | -1.3 points |
| Q2 2025 | 32% | -0.7 points |
| Q1 2025 | 31% | +2.6 points |
| Q4 2024 | 30% | +2 points |
ORCL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ORCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4B | -$5B |
| Q2 2026 | -$1.9B | +$1.1B |
| Q1 2026 | -$11.5B | -16275% |
| Q4 2025 | -$10B | -$7.3B |
| Q3 2025 | -$362M | -107% |
| Q2 2025 | -$2.9B | -189% |
| Q1 2025 | $71M | -98% |
| Q4 2024 | -$2.7B | -$1.7B |
ORCL has burned cash in seven of the last eight quarters: −$28.7B over the past year, against −$5.9B the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ORCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ORCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +86M shares |
| 1 year | +3.1% | +91M shares |
| 3 years | +6.3% | +177M shares |
| 5 years | +4.9% | +139M shares |
| Available history | -9.9% | -331M shares |
ORCL has 3B diluted shares, up 3.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $95M |
| Q2 2025 | $150M |
| Q1 2025 | $150M |
| Q4 2024 | $150M |
| Q3 2024 | $150M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ORCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.2x | Very low |
ORCL has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ORCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 23.0 | Neutral |
ORCL's weekly RSI is 42 (neutral) and its Stochastic is 23 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ORCL PE vs Technology Sector
| Metric | ORCL | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 28% below |
| PE % | 28 | 35 | 7 pts below |
ORCL is trading at 20x earnings, a 28% discount to the Technology sector's median of 28x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ORCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.1 | 3.1% below |
| 20 week MA | $137.6 | 7.7% below |
| 50 week MA | $160.3 | 21% below |
| 100 week MA | $181.4 | 30% below |
| 200 week MA | $151.9 | 16% below |
ORCL is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
ORCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $53.5 | $65.0 | +22% |
| 2021 | $65.0 | $89.7 | +38% |
| 2022 | $89.7 | $80.9 | -9.9% |
| 2023 | $80.9 | $105.4 | +30% |
| 2024 | $105.4 | $169.0 | +60% |
| 2025 | $169.0 | $198.0 | +17% |
| 2026 YTD | $198.0 | $127.1 | -36% |
ORCL has the edge over HIMS on returns for 2026, with the stronger performance.